替吉奥联合紫杉醇二线治疗复发及转移性胃癌临床疗效观察

The clinical study of domestic compound Tegafur capsulecombined with Paclitaxel second-line therapy for patients with advanced or metastatic gastric cancer

目的回顾性分析国产替吉奥(维康达)联合紫杉醇治疗复发、转移性胃癌患者的近期疗效及毒副反应。方法 16例复发、转移性胃癌患者使用国产替吉奥联合紫杉醇二线化疗,替吉奥根据体表面积按推荐剂量口服1～14 d,紫杉醇135mg/m2第1天静脉注射,每3周重复。所有患者均接受2周期以上化疗,2周期后评价疗效及毒副反应。结果 16例患者4例部分缓解(PR),7例稳定(SD),5例进展(PD),有效率25%,临床获益率68.75%,近期毒副反应较轻。结论替吉奥联合紫杉醇作为二线化疗方案治疗复发、转移性胃癌,临床获益率较高,值得进一步研究。

Objective To evaluate the efficacy and toxicity of domestic compound Tegafur capsule combined with Paclitaxel in the second-line treatment for patients with advanced or metastatic gastric carcinoma.Methods Sixteen patients with advanced or metastatic gastric carcinoma were second-line treated with domestic compound Tegafur capsule combined with Paclitaxel.The domestic compound Tegafur capsule was given orally according to body surface area,d 1-14,Paclitaxel 135 mg/m2,d1,q3w.Each patient was treated at least for two cycles.The efficacy and toxicity were evaluated after 2cycles of treatment.Results Four patients achieved partial response（PR）,seven patients had stable disease（SD）,and five patients had progression disease（PD）.The overall response rate was 25%.The clinical beneficial response was 68.75%.The adverse reaction was mild.Conclusion The domestic compound Tegafur capsule combined with Paclitaxel is effective and well tolerated as the second-line therapy for patients with advanced or metastatic gastric carcinoma.